OVERSEA CHINESE BANKING Corp Ltd Increases Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

OVERSEA CHINESE BANKING Corp Ltd boosted its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 107.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,855 shares of the medical device company's stock after buying an additional 3,558 shares during the period. OVERSEA CHINESE BANKING Corp Ltd's holdings in DexCom were worth $533,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Versant Capital Management Inc purchased a new position in shares of DexCom in the 4th quarter valued at approximately $25,000. Private Trust Co. NA raised its holdings in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after purchasing an additional 245 shares in the last quarter. Larson Financial Group LLC raised its holdings in DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after purchasing an additional 137 shares in the last quarter. Heck Capital Advisors LLC purchased a new position in DexCom during the fourth quarter valued at $38,000. Finally, SBI Securities Co. Ltd. bought a new stake in shares of DexCom during the 4th quarter valued at $49,000. 97.75% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 14,076 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the transaction, the chief operating officer now owns 313,497 shares in the company, valued at $22,063,918.86. This trade represents a 4.30 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock worth $8,044,178 in the last three months. 0.30% of the stock is owned by company insiders.

Remove Ads

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Citigroup increased their price target on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research note on Tuesday, March 4th. Robert W. Baird raised shares of DexCom from a "neutral" rating to an "outperform" rating and raised their target price for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and lifted their target price for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Finally, Morgan Stanley lifted their price objective on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research note on Friday, February 14th. Five research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, DexCom has a consensus rating of "Moderate Buy" and a consensus target price of $99.82.

DexCom Stock Performance

Shares of NASDAQ:DXCM traded down $1.77 during midday trading on Tuesday, hitting $73.55. The company had a trading volume of 3,240,370 shares, compared to its average volume of 3,915,036. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a fifty day moving average of $83.24 and a two-hundred day moving average of $77.07. The company has a market cap of $28.74 billion, a price-to-earnings ratio of 51.43, a PEG ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, equities research analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.